In Brief: Micro Therapeutics
This article was originally published in The Gray Sheet
Executive Summary
Micro Therapeutics: Launches ProStream multiple sidehole infusion wire for use in delivering pharmacologic agents into the peripheral vasculature. The device, cleared by FDA Jan. 2, uses a "fixed hub" design and an "integrated inner core wire" for easier placement into peripheral vessels, the firm explains. ProStream, which can be used in conjunction with Micro's Cragg-McNamara valved infusion catheters, will be marketed and sold in the U.S. through the firm's eight-person direct sales force. The company expects CE Mark approval by the first quarter of next year...
You may also be interested in...
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.
Swisse Supplements Take Bigger Slice Of Chinese Market
Australian-heritage Swisse grew its share of China's supplements market in 2023 by delivering tailored products to an increasingly health conscious population.